BenevolentAI
ben a highly potent and selective inhibitor has entered phase a clinical development | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
March 2024
Slide
22 of 23
Related slides by other companies
Vincera
SPAC
September 2020
highly selective and potent inhibitor a | Vincera
Erasca
IPO
July 2021
we believe eras is the most potent inhibitor in development | Erasca
Imara
Mergers and Acquisitions
October 2022
clinical development strategy i | Imara
ATAI
Investor Presentation
March 2023
low doses enhanced learning and memory significantly reverses memory deficits memory challenged young dogs phase scopolamine memory challenge clinical and non clinical studies provide consistent evidence of pro cognitive effect along inverted bell shaped dose response curve learnings in reversed in | ATAI
Other recent decks by BenevolentAI
See all presentations (10 decks)
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Investor Conference
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io